Novo Nordisk and United Bio-Technology reported positive phase 2 trial results for UBT251, a triple receptor agonist drug targeting obesity and type 2 diabetes. UBT251 outperformed semaglutide by reducing HbA1c levels by 2.16% versus 1.77%, and achieving nearly 10% weight loss compared to 4.8% with semaglutide. The drug also improved waist circumference, blood pressure, and lipid levels with no unexpected safety issues. Novo Nordisk plans global phase 2 and phase 3 trials, with results expected from ongoing studies in 2027.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
